I believe the SMART study team have submitted a response to Justin Stebbing and Angus Dalgleish’s comments in the Lancet Infectious Diseases, that was referred to in a previous post:
The explanation that the huge discrepancy in the number of deaths in the US and non US sites was due to the fact that non US sites started to enrol participants 2-3 years later than US sites, was addressed in the comments in the Lancet Infectious Diseases.
Here is the relevant part:
“Whereas most non-US sites commenced patient recruitment 2—3 years after the US sites, it is unlikely that longer protocol exposure could account for this difference. We are told that there were 38 deaths in the first year and 47 deaths thereafter. Hence, assuming that all six non-US deaths occurred in the first year, there remain 32 deaths (38 minus six) in the USA from the first year of the study—about five-fold more than expected based on the non-US mortality rate”.
Whatever explanation is to be offered by the SMART team, even if turns out to be consistent with their conclusions, the following questions remain.
Why was information on the distribution of deaths withheld for so many years?
Why was this information, when it did appear in the article by Kuller et al in PLoS last year, ignored by community commentators to whom HIV infected people and their advocates look to for help.?
Did they not notice it? (I did not).
Did they think it was of no significance?
Hopefully the SMART team’s response will put an end to this mystery of why, with more or less the same number of participants in US and non US sites, 79 people died at US sites while there were only 6 deaths at sites outside the US.